LISA MORRIS: Open Payments
NPI 1730710344 · AMSTERDAM, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$316 in 16 payments from 11 companies in 2025. Trend: 2023 $122 · 2024 $119 · 2025 $316
Food & beverage: $316
| Company | Payments | Amount |
|---|---|---|
| Exeltis, USA Inc. | 3 | $59 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $45 |
| ABBVIE INC. | 2 | $36 |
| Amgen Inc. | 2 | $31 |
| Organogenesis Inc. | 1 | $28 |
| Lilly USA, LLC | 1 | $25 |
| GlaxoSmithKline, LLC. | 1 | $20 |
| Boston Scientific Corporation | 1 | $19 |
| Novo Nordisk Inc | 1 | $19 |
| Organon LLC | 1 | $19 |
Products named: SLYND, XIFAXAN, OTEZLA, PURAPLY WOUND MATRIX, ZEPBOUND, VRAYLAR, BEXSERO, Bulkamid.
Industry payments across NY — which companies pay providers there.
